111 related articles for article (PubMed ID: 22894916)
1. Macro CK2 accumulation in tenofovir-treated HIV patients is facilitated by CK oligomer stabilization but is not predictive for pathology.
Schmid H; Tokarska-Schlattner M; Füeßl B; Röder M; Kay L; Attia S; Lederer SR; Goebel FD; Schlattner U; Bogner JR
Antivir Ther; 2013; 18(2):193-204. PubMed ID: 22894916
[TBL] [Abstract][Full Text] [Related]
2. Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK.
Schmid H; Mühlbayer D; Röling J; Sternfeld T; Jülg B; Schlattner U; Nelson PJ; Bogner JR; Wallimann T; Goebel FD
Antivir Ther; 2006; 11(8):1071-80. PubMed ID: 17302377
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration.
Bickel M; Khaykin P; Stephan C; Schmidt K; Buettner M; Amann K; Lutz T; Gute P; Haberl A; Geiger H; Brodt HR; Jung O
HIV Med; 2013 Nov; 14(10):633-8. PubMed ID: 23980564
[TBL] [Abstract][Full Text] [Related]
4. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Maggi P; Montinaro V; Bellacosa C; Pietanza S; Volpe A; Graziano G; Strippoli GF; Angarano G
AIDS Patient Care STDS; 2012 Jan; 26(1):5-11. PubMed ID: 22136504
[TBL] [Abstract][Full Text] [Related]
5. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Pradat P; Le Pogam MA; Okon JB; Trolliet P; Miailhes P; Brochier C; Maynard M; Bailly F; Zoulim F; Cotte L
J Viral Hepat; 2013 Sep; 20(9):650-7. PubMed ID: 23910650
[TBL] [Abstract][Full Text] [Related]
6. Increase in serum mitochondrial creatine kinase levels induced by tenofovir administration.
Watanabe D; Yoshino M; Yagura H; Hirota K; Yonemoto H; Bando H; Yajima K; Koizumi Y; Otera H; Tominari S; Nishida Y; Kuwahara T; Uehira T; Shirasaka T
J Infect Chemother; 2012 Oct; 18(5):675-82. PubMed ID: 22350406
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
Fux CA; Simcock M; Wolbers M; Bucher HC; Hirschel B; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Elzi L; Furrer H;
Antivir Ther; 2007; 12(8):1165-73. PubMed ID: 18240857
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.
Buchacz K; Brooks JT; Tong T; Moorman AC; Baker RK; Holmberg SD; Greenberg A;
HIV Med; 2006 Oct; 7(7):451-6. PubMed ID: 16925731
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir.
Bech A; Van Bentum P; Nabbe K; Gisolf J; Richter C; De Boer H
HIV Med; 2012 Oct; 13(9):558-63. PubMed ID: 22462533
[TBL] [Abstract][Full Text] [Related]
10. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
Agbaji OO; Agaba PA; Idoko JA; Taiwo B; Murphy R; Kanki P; Ekong E
West Afr J Med; 2011; 30(3):164-8. PubMed ID: 22120479
[TBL] [Abstract][Full Text] [Related]
11. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
Andrade-Fuentes K; Mata-Marín JA; López-De León JI; Manjarrez-Téllez B; Ramírez JL; Gaytan-Martínez J
AIDS Patient Care STDS; 2015 Apr; 29(4):181-5. PubMed ID: 25101526
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
López S; Negredo E; Garrabou G; Puig J; Ruiz L; Sanjurjo E; Ramos X; Infante AB; Casademont J; Cardellach F; Clotet B; Miró O
AIDS Res Hum Retroviruses; 2006 Jan; 22(1):33-9. PubMed ID: 16438643
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
Woratanarat K; Kanjanabuch T; Suankratay C
J Med Assoc Thai; 2013 Apr; 96(4):432-9. PubMed ID: 23691697
[TBL] [Abstract][Full Text] [Related]
15. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Hall AM; Edwards SG; Lapsley M; Connolly JO; Chetty K; O'Farrell S; Unwin RJ; Williams IG
Am J Kidney Dis; 2009 Dec; 54(6):1034-42. PubMed ID: 19783343
[TBL] [Abstract][Full Text] [Related]
16. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Judd A; Boyd KL; Stöhr W; Dunn D; Butler K; Lyall H; Sharland M; Shingadia D; Riordan A; Gibb DM
AIDS; 2010 Feb; 24(4):525-34. PubMed ID: 20139752
[TBL] [Abstract][Full Text] [Related]
17. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Havens PL; Kiser JJ; Stephensen CB; Hazra R; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Gordon CM; Mulligan K;
Antimicrob Agents Chemother; 2013 Nov; 57(11):5619-28. PubMed ID: 24002093
[TBL] [Abstract][Full Text] [Related]
18. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
[TBL] [Abstract][Full Text] [Related]
19. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
Vrouenraets SM; Fux CA; Wit FW; Garcia EF; Furrer H; Brinkman K; Hoek FJ; Abeling NG; Krediet RT; Reiss P;
AIDS; 2011 Nov; 25(17):2149-55. PubMed ID: 21857491
[TBL] [Abstract][Full Text] [Related]
20. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
Ray AS; Myrick F; Vela JE; Olson LY; Eisenberg EJ; Borroto-Esodo K; Miller MD; Fridland A
Antivir Ther; 2005; 10(3):451-7. PubMed ID: 15918336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
